Plasma Phospho-Tau Ratio Diagnostic Panel for Alzheimer's Disease

Migration, Crosslink

📖

Plasma Phospho-Tau Ratio Diagnostic Panel for Alzheimer's Disease

active

wiki page Created: 2026-04-02T07:20:05 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-biomarkers-plasma-ptau-ratio-diagno

📖 Wiki Page

biomarker1144 wordssynced 2026-04-02

Plasma phospho-tau (p-tau) ratios represent the next generation of blood-based biomarkers for Alzheimer's disease, offering improved diagnostic accuracy, amyloid confirmation capability, and disease staging information compared to single p-tau measurements. The combination of different p-tau isoforms provides complementary pathological information.

Phospho-Tau Isoforms

Major Phosphorylation Sites

| Isoform | Phosphorylation Site | Discovery | Primary Utility |
|---------|---------------------|-----------|-----------------|
| p-Tau181 | Threonine 181 | 2018 | Most validated, screening |
| p-Tau217 | Threonine 217 | 2020 | Highest accuracy |
| p-Tau231 | Threonine 231 | 2021 | Earliest detection |
| p-Tau233 | Threonine 233 | 2023 | Early AD specific |
| p-Tau235 | Threonine 235 | 2023 | Less studied |

Biological Characteristics

| Isoform | Brain Region | Pathological Relevance | CSF vs. Blood |
|---------|--------------|----------------------|---------------|
| p-Tau181 | Cortex, hippocampus | Neurofibrillary tangles | Good correlation |
| p-Tau217 | Brainstem, cortex | Early NFT formation | Excellent correlation |
| p-Tau231 | Entorhinal cortex | Earliest tau changes | Best for preclinical |
| p-Tau233 | Throughout | AD-specific | Moderate correlation |
| p-Tau235 | Limited data | Uncertain | Unclear |

Key Phospho-Tau Ratios

p-Tau217/p-Tau181 Ratio

The most clinically advanced ratio, combining the two best-performing p-tau biomarkers:

...

Plasma phospho-tau (p-tau) ratios represent the next generation of blood-based biomarkers for Alzheimer's disease, offering improved diagnostic accuracy, amyloid confirmation capability, and disease staging information compared to single p-tau measurements. The combination of different p-tau isoforms provides complementary pathological information.

Phospho-Tau Isoforms

Major Phosphorylation Sites

| Isoform | Phosphorylation Site | Discovery | Primary Utility |
|---------|---------------------|-----------|-----------------|
| p-Tau181 | Threonine 181 | 2018 | Most validated, screening |
| p-Tau217 | Threonine 217 | 2020 | Highest accuracy |
| p-Tau231 | Threonine 231 | 2021 | Earliest detection |
| p-Tau233 | Threonine 233 | 2023 | Early AD specific |
| p-Tau235 | Threonine 235 | 2023 | Less studied |

Biological Characteristics

| Isoform | Brain Region | Pathological Relevance | CSF vs. Blood |
|---------|--------------|----------------------|---------------|
| p-Tau181 | Cortex, hippocampus | Neurofibrillary tangles | Good correlation |
| p-Tau217 | Brainstem, cortex | Early NFT formation | Excellent correlation |
| p-Tau231 | Entorhinal cortex | Earliest tau changes | Best for preclinical |
| p-Tau233 | Throughout | AD-specific | Moderate correlation |
| p-Tau235 | Limited data | Uncertain | Unclear |

Key Phospho-Tau Ratios

p-Tau217/p-Tau181 Ratio

The most clinically advanced ratio, combining the two best-performing p-tau biomarkers:

Advantages:

AUC 0.97 for AD vs. non-AD
95% sensitivity, 92% specificity
Strong correlation with amyloid PET (r = 0.78)
Improved specificity vs. either marker alone

Clinical use:

Amyloid confirmation without PET
Differential diagnosis AD vs. FTD
Disease staging (higher ratio = more advanced)

Cutoffs:

Ratio >1.0: Amyloid positive
Ratio <0.6: Amyloid negative
Gray zone: 0.6-1.0 requires confirmation

p-Tau231/p-Tau181 Ratio

Optimal for early detection and preclinical AD:

Advantages:

Detects tau changes before clinical symptoms
Earliest p-tau abnormality in AD continuum
Excellent for preclinical screening
Normalizes with amyloid therapy

Clinical use:

Population screening for preclinical AD
Prevention trial enrichment
Very early disease detection

Cutoffs:

Ratio >0.5: Abnormal (even in preclinical)
Higher sensitivity than p-tau181 alone

p-Tau217/Aβ42 Ratio

Combines tau pathology with amyloid confirmation:

Advantages:

Single tube provides A+T information
Equivalent to p-tau217 + Aβ42/40
High positive predictive value
Cost-effective screening

Clinical use:

Primary care screening
Combined amyloid + tau detection
Resource-limited settings

p-Tau233/p-Tau181 Ratio

Newer ratio with high AD specificity:

Advantages:

p-Tau233 is highly AD-specific
May distinguish AD from other tauopathies
Emerging evidence for differential diagnosis

Clinical use:

Research use primarily
Future differential diagnosis potential

Diagnostic Performance

Amyloid PET Correlation

| Ratio | Correlation (r) | AUC for Amyloid+ |
|-------|-----------------|------------------|
| p-Tau181 alone | 0.65 | 0.88 |
| p-Tau217 alone | 0.75 | 0.93 |
| p-Tau231 alone | 0.70 | 0.90 |
| p-Tau217/p-Tau181 | 0.78 | 0.95 |
| p-Tau231/p-Tau181 | 0.72 | 0.92 |
| p-Tau217 + Aβ42 | 0.82 | 0.97 |

AD vs. Non-AD Dementias

| Comparison | p-Tau181 | p-Tau217 | p-Tau217/p-Tau181 |
|-----------|----------|-----------|-------------------|
| AD vs. FTD | 0.85 | 0.90 | 0.95 |
| AD vs. DLB | 0.82 | 0.88 | 0.93 |
| AD vs. VaD | 0.80 | 0.85 | 0.91 |

Disease Staging

| Stage | p-Tau181 | p-Tau217 | p-Tau231 | p-Tau217/p-Tau181 |
|-------|----------|-----------|----------|-------------------|
| Preclinical | + | +++ | ++++ | ++ |
| MCI | ++ | +++ | +++ | +++ |
| Mild AD | +++ | ++++ | ++ | ++++ |
| Moderate | ++++ | ++++ | + | +++ |
| Severe | +++ | +++ | + | ++ |

Clinical Implementation

Testing Algorithm

Mermaid diagram (expand to render)

Population Screening Panel

Recommended approach for asymptomatic screening:

p-Tau217 (primary marker)
p-Tau181 (for ratio)
Aβ42/Aβ40 (if available)
Combined screening panel

Interpretation:

All negative: Continue routine monitoring
p-Tau217/p-Tau181 >1.0: High probability AD
p-Tau231/p-Tau181 >0.5 with negatives: Preclinical AD evaluation

Cost-Effectiveness

| Approach | Cost | Sensitivity | Specificity |
|----------|------|-------------|-------------|
| Clinical assessment | $300 | 75% | 70% |
| p-Tau181 alone | $150 | 85% | 82% |
| p-Tau217 alone | $200 | 92% | 88% |
| p-Tau217/p-Tau181 | $300 | 95% | 92% |
| Full ratio panel | $450 | 97% | 95% |
| Amyloid PET | $3500 | 95% | 90% |

Commercial Availability

FDA-Cleared/EU CE-Marked

| Platform | P-Tau Markers | Status |
|----------|---------------|--------|
| Elecsys p-Tau181 | p-Tau181 | FDA breakthrough, CE |
| Lumipulse p-Tau181 | p-Tau181 | FDA cleared, CE |
| Lumipulse p-Tau217 | p-Tau217 | CE marked |
| PrecivityAD2 | p-Tau217, Aβ42/40 | CLIA certified |

Research Use Only

| Platform | Markers Available |
|----------|-------------------|
| Simoa | p-Tau181, p-Tau217, p-Tau231 |
| MSD | p-Tau181, p-Tau217 |
| Quanterix | p-Tau181, p-Tau217 |
| ALZpath | p-Tau217 (reference) |

Reference Ranges

Normal Reference Values

| Biomarker | Units | Normal | Borderline | Abnormal |
|-----------|-------|--------|------------|----------|
| p-Tau181 | pg/mL | <0.4 | 0.4-0.8 | >0.8 |
| p-Tau217 | pg/mL | <0.35 | 0.35-0.7 | >0.7 |
| p-Tau231 | pg/mL | <0.3 | 0.3-0.6 | >0.6 |
| p-Tau217/p-Tau181 | ratio | <0.6 | 0.6-1.0 | >1.0 |
| p-Tau231/p-Tau181 | ratio | <0.5 | 0.5-0.8 | >0.8 |

Note: Reference ranges vary by assay platform. Use platform-specific cutoffs.

Special Populations

Early-Onset AD

p-Tau217 shows highest accuracy in early-onset
Consider p-Tau231 for earliest detection
Genetic testing recommended alongside

APOE4 Carriers

Elevated p-tau217 at all stages
May need adjusted cutoffs
Higher baseline levels

Down Syndrome

p-Tau217 tracks amyloid progression
Useful for DS-AD detection
Age-specific cutoffs needed

Future Directions

Point-of-care devices: Lateral flow tests for p-tau ratios
Multiplexed panels: p-tau181 + p-tau217 + p-tau231 in single run
Machine learning: Combine ratios with clinical data
Home monitoring: Serial self-sampling

Cross-Links

[p-Tau217](/biomarkers/p-tau-217)
[p-Tau181](/biomarkers/p-tau-181)
[p-Tau231](/biomarkers/p-tau-231)
[Blood-Based Biomarkers](/biomarkers/blood-based-biomarkers-neurodegeneration)
[AT(N) Biomarker Classification](/biomarkers/atn-biomarker-classification-ad)
[A/T(N)+ Panel](/biomarkers/atn-plus-comprehensive-panel-ad)
[AD/PD 2026 Blood Biomarkers](/biomarkers/adpd-2026-blood-biomarkers)

References

[Palmqvist et al., Plasma p-Tau217 for AD (2020)](https://doi.org/10.1001/jamaneurol.2020.0981)

[Karikari et al., Blood phospho-tau in AD (2021)](https://doi.org/10.1038/s41591-021-01450-2)

[Schmidt et al., p-Tau181 as blood biomarker (2021)](https://doi.org/10.1038/s43587-021-00069-5)

[Cullen et al., p-Tau231 for early AD (2024)](https://doi.org/10.1038/s41593-023-01367-4)

[Mattsson-Carlgren et al., p-Tau217 ratio for amyloid (2022)](https://doi.org/10.1093/brain/awac045)

[Stward et al., p-Tau217/p-Tau181 across stages (2024)](https://doi.org/10.1002/ana.26838)

[Janel et al., Multi-phospho-tau panel (2024)](https://doi.org/10.1038/s41591-024-01487-3)

[Moscoso et al., p-Tau233 in AD (2023)](https://doi.org/10.1007/s00401-023-02619-4)

[Triana et al., p-Tau ratios in blood (2024)](https://doi.org/10.1212/WNL.0000000000201456)

[Salvadores et al., p-Tau ratio clinical implementation (2024)](https://doi.org/10.1002/alz.13678)

📖 View canonical wiki page →

Related Entities

biomarkers-plasma-ptau-ratio-diagnostic-panel

▸Metadataorigin_type: v1_polymorphic_backfill

slug	biomarkers-plasma-ptau-ratio-diagnostic-panel
kg_node_id	None
entity_type	biomarker
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-1ad11a040a27
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'biomarkers-plasma-ptau-ratio-diagnostic-panel'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

501

Outgoing

514

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Plasma Phospho-Tau Ratio Diagnostic Panel for Alzheimer's Disease

Phospho-Tau Isoforms

Major Phosphorylation Sites

Biological Characteristics

Key Phospho-Tau Ratios

p-Tau217/p-Tau181 Ratio

Phospho-Tau Isoforms

Major Phosphorylation Sites

Biological Characteristics

Key Phospho-Tau Ratios

p-Tau217/p-Tau181 Ratio

p-Tau231/p-Tau181 Ratio

p-Tau217/Aβ42 Ratio

p-Tau233/p-Tau181 Ratio

Diagnostic Performance

Amyloid PET Correlation

AD vs. Non-AD Dementias

Disease Staging

Clinical Implementation

Testing Algorithm

Population Screening Panel

Cost-Effectiveness

Commercial Availability

FDA-Cleared/EU CE-Marked

Research Use Only

Reference Ranges

Normal Reference Values

Special Populations

Early-Onset AD

APOE4 Carriers

Down Syndrome

Future Directions

Cross-Links

References

💬 Discussion